Proceedings of the National Academy of Sciences · 2024 · 16 citations · 76 references
Life SciencesGeneticsMolecular BiologyDna RepairMolecular NeuroscienceNeurodegenerationDna DamageDna Repair DefectsHuntington DiseaseMolecular Basis Of NeurodegenerationNeurodegenerative DiseasesNeurodegenerative DisordersDna Repair-associated NeurodegenerationFamilial Neurodegenerative DiseaseHtt GeneParp InhibitionPoly(adp-ribose) Polymerase SignalingPoly(adp-ribose) Polymerase-mediated RepairPolyglutamine DiseasesPolyglutamine Expansion Disorders
) gene, translating to an expanded polyglutamine tract in the HTT protein. Age at disease onset correlates to CAG repeat length but varies by decades between individuals with identical repeat lengths. Genome-wide association studies link HD modification to DNA repair and mitochondrial health pathways. Clinical studies show elevated DNA damage in HD, even at the premanifest stage. A major DNA repair node influencing neurodegenerative disease is the PARP pathway. Accumulation of poly adenosine diphosphate (ADP)-ribose (PAR) has been implicated in Alzheimer and Parkinson diseases, as well as cerebellar ataxia. We report that HD mutation carriers have lower cerebrospinal fluid PAR levels than healthy controls, starting at the premanifest stage. Human HD induced pluripotent stem cell-derived neurons and patient-derived fibroblasts have diminished PAR response in the context of elevated DNA damage. We have defined a PAR-binding motif in HTT, detected HTT complexed with PARylated proteins in human cells during stress, and localized HTT to mitotic chromosomes upon inhibition of PAR degradation. Direct HTT PAR binding was measured by fluorescence polarization and visualized by atomic force microscopy at the single molecule level. While wild-type and mutant HTT did not differ in their PAR binding ability, purified wild-type HTT protein increased in vitro PARP1 activity while mutant HTT did not. These results provide insight into an early molecular mechanism of HD, suggesting possible targets for the design of early preventive therapies.
76
Murielle Masson, Claude Niedergang, Valérie Schreiber et al. · Molecular and Cellular Biology · 1998 · 904 citations · Full text
Identification of Genetic Factors that Modify Clinical Onset of Huntington’s Disease
Jong‐Min Lee, Vanessa C. Wheeler, Michael J. Chao et al. · Cell · 2015 · 675 citations · Full text